EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas

Natalie M Meléndez-Vázquez iD, Candelaria Gomez-Manzano iD, Filipa Godoy-Vitorino iD

Viruses · 2024

DOI: 10.3390/v16111775 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Natalie M Meléndez-Vázquez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00918, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Gastrointestinal Microbiome, Glioma, Oncolytic Virotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIMHD NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most prevalent malignant brain tumor. Current standard-of-care treatments offer limited benefits for patient survival. Virotherapy is emerging as a novel strategy to use oncolytic viruses (OVs) for the treatment of GBM. These engineered and non-engineered viruses infect and lyse cancer cells, causing tumor destruction without harming healthy cells. Recent advances in genetic modifications to OVs have helped improve their targeting capabilities and introduce therapeutic genes, broadening the therapeutic window and minimizing potential side effects. The efficacy of oncolytic virotherapy can be enhanced by combining it with other treatments such as immunotherapy, chemotherapy, or radiation. Recent studies suggest that manipulating the gut microbiome to enhance immune responses helps improve the therapeutic efficacy of the OVs. This narrative review intends to explore OVs and their role against solid tumors, especially GBM while emphasizing the latest technologies used to enhance and improve its therapeutic and clinical responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGastrointestinal MicrobiomeGliomaOncolytic VirotherapyAnimalsHumansCombined Modality TherapyGlioblastomaImmunotherapyOncolytic Viruses

Stichwörter der Autor:innen

combinatory therapiesglioblastomagut microbiometherapeutic efficacyviroimmunotherapy

Autor:innen und Institutionen

  • Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00918, USA.
  • Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Natalie M Meléndez-Vázquez, Candelaria Gomez-Manzano, Filipa Godoy-Vitorino

Förderung

  • NCI NIH HHS
  • NIMHD NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health (NIH) UPR/MDACC
  • NIGMS-RISE Research Initiative for Scientific Enhancement
  • Center for Collaborative Research in Minority Health and Health Disparities (RCMI)
  • NIH

Zitieren

APA

Meléndez-Vázquez, N. M., Gomez-Manzano, C., & Godoy-Vitorino, F. (2024). Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses. https://doi.org/10.3390/v16111775

Vancouver

Meléndez-Vázquez NM, Gomez-Manzano C, Godoy-Vitorino F. Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses. 2024. doi:10.3390/v16111775

BibTeX
@article{MelndezVzquez2024,
  author = {Meléndez-Vázquez, Natalie M and Gomez-Manzano, Candelaria and Godoy-Vitorino, Filipa},
  title = {Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16111775}
}
Kostenlos starten →